2017 May Prove To Be A Good Year for AstraZeneca
Based in England, one of the biggest pharmaceutical companies AstraZeneca, has faced a tough time in the past few years. Sharp decline in revenue was especially high for AstraZeneca in 2012, when they had already lost the patent for the Arimidex (breast cancer drug), Nexium (proton pump inhibitor), Crestor (cholesterol drug) and were about to lose the patent for Seroquel (antipsychotic medicine).
Patent losses and generic competition had huge impact on revenue as well as net profits in last few years for AstraZeneca.
AstraZeneca have been putting in lot of efforts to make things correct and the results are showing. Tagrisso (used to treat a specific kind of non-small cell lung cancer) has witnessed a quick sequential increase of 45 percent, generating $133 million in the 3rd quarter of 2016, and overall revenue has increased 33 percent quarter on quarter. Tagrisso’s good results appear to be continue. Additionally, Brilinta (used to reduce the risk of having a stroke or severe heart issues after a heart attack or angina) is also offering profits, it already generated $619 million previous year and is now believed to bring in a revenue of $2 billion a year.
Moving forward, the Mystic lung cancer trial will post outcomes in the 1st half of 2017, and outcomes from head and neck cancer studies – which were for the short term halted in October – are believed to come out in the 2nd half of the year. There is hope that even partial good results from these studies will yield $7 billion a year in revenue.